IGI Logo

Sun Pharmaceutical Industries is currently trading at Rs. 970.15, up by 10.95 points or 1.14% from its previous closing of Rs. 959.20 on the BSE.

The scrip opened at Rs. 966.45 and has touched a high and low of Rs. 978.30 and Rs. 961.60 respectively. So far 47833 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 1071.90 on 30-Jan-2023 and a 52 week low of Rs. 789.75 on 17-Jun-2022.

Last one week high and low of the scrip stood at Rs. 978.30 and Rs. 937.20 respectively. The current market cap of the company is Rs. 232855.46 crore.

The promoters holding in the company stood at 54.48%, while Institutions and Non-Institutions held 36.12% and 9.41% respectively.

Sun Pharmaceutical Industries has entered into a licensing agreement with Philogen S.p.A for commercializing Philogen’s specialty product, Nidlegy (Daromun) in the territories of Europe, Australia and New Zealand. Nidlegy, currently in Phase III clinical trials, is a new anti-cancer biopharmaceutical which is being developed by Philogen for the treatment of melanoma and non-melanoma skin cancers.

Under the terms of the agreement, Sun Pharma will have exclusive rights to commercialise Nidlegy for indications of skin cancers in the territories of Europe, Australia and New Zealand. Philogen will complete pivotal clinical trials for the product in Europe, pursue Marketing Authorization with the regulatory authorities and manufacture commercial supplies. Sun Pharma will be responsible for commercialization activities. The two partner companies will share post commercialization economics in about 50:50 ratio. Other financial terms were not disclosed. Philogen will retain the IP rights for Nidlegy for other territories and indications other than skin cancers.

Sun Pharmaceutical Industries is the world's fourth largest specialty generic pharmaceutical company and India's top pharmaceutical company.